S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Forecast, Price & News

$2.13
+0.13 (+6.50%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.03
$2.15
50-Day Range
$2.00
$2.74
52-Week Range
$1.45
$3.70
Volume
8,564 shs
Average Volume
N/A
Market Capitalization
$28.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

CASI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
369.5% Upside
$10.00 Price Target
Short Interest
Healthy
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.00mentions of CASI Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.23) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

340th out of 963 stocks

Biological Products, Except Diagnostic Industry

52nd out of 155 stocks


CASI stock logo

About CASI Pharmaceuticals (NASDAQ:CASI) Stock

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Price History

CASI Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
CASI Pharmaceuticals, Inc. Q2 Loss Widens
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
CASI - CASI Pharmaceuticals, Inc.
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Company Calendar

Last Earnings
8/11/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CASI
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+369.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-85.72%

Debt

Sales & Book Value

Annual Sales
$43.11 million
Book Value
$3.28 per share

Miscellaneous

Free Float
10,492,000
Market Cap
$28.38 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Wei-Wu He Ph.D. (Age 58)
    Chairman & CEO
    Comp: $565.36k
  • Dr. Wei Zhang Ph.D. (Age 63)
    Pres
    Comp: $1.13M
  • Dr. Alexander A. Zukiwski M.D. (Age 66)
    Exec. VP & Chief Medical Officer
    Comp: $514.79k
  • Ms. Kun Qian (Age 41)
    VP & Global Controller
  • Ms. Chunhua Wang (Age 51)
    Chief Operating Officer
  • Ms. Wei Gao (Age 42)
    Gen. Counsel
  • Dr. James E. Goldschmidt Ph.D.
    Chief Bus. Devel. Officer
  • Mr. Fuqiang Zhang (Age 54)
    Chief Commercial Officer
  • Ms. Amanda Cui
    VP & Global Controller













CASI Stock - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price forecast for 2023?

2 equities research analysts have issued 12 month target prices for CASI Pharmaceuticals' stock. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 369.5% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2023?

CASI Pharmaceuticals' stock was trading at $1.79 at the beginning of the year. Since then, CASI shares have increased by 19.0% and is now trading at $2.13.
View the best growth stocks for 2023 here
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to the consensus estimate of $10.09 million. CASI Pharmaceuticals had a negative net margin of 93.92% and a negative trailing twelve-month return on equity of 92.06%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals's stock reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.17%) and Northern Trust Corp (0.08%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He.
View institutional ownership trends
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.13.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $28.38 million and generates $43.11 million in revenue each year. The biotechnology company earns $-41,010,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

The company employs 224 workers across the globe.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at 861065086063, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.

This page (NASDAQ:CASI) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -